Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
Authors
Keywords
Nivolumab, Pembrolizumab, PD-1 inhibitor, Ipilimumab, Immune checkpoint inhibitors, Lipase, Diabetes, Pancreatitis, Diabetes mellitus, Immune-related adverse events
Journal
EUROPEAN JOURNAL OF CANCER
Volume 149, Issue -, Pages 1-10
Publisher
Elsevier BV
Online
2021-03-31
DOI
10.1016/j.ejca.2021.02.017
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy
- (2018) Thiru Prasanna et al. Immunotherapy
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
- (2018) Yael Eshet et al. Cancer Immunology Research
- Atrophic Exocrine Pancreatic Insufficiency Associated with Anti-PD1 Therapy
- (2016) G. Long et al. ANNALS OF ONCOLOGY
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab
- (2016) Claire F. Friedman et al. JNCI-Journal of the National Cancer Institute
- Acute Pancreatitis: What's the Score?
- (2015) Dick C. Kuo et al. JOURNAL OF EMERGENCY MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Significant elevations of serum lipase not caused by pancreatitis: a systematic review
- (2015) Ahmer M. Hameed et al. HPB
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More